Roots Analysis Identifies Four Leading Biosimilar Companies for 2025

Market research firm Roots Analysis has identified four key companies expected to play significant roles in the biosimilar market in 2025. These companies are Amgen, Pfizer, Sandoz, and Celltrion.

Biosimilars are highly similar versions of original biologic medicines, demonstrating no clinically meaningful differences. Their development is driven by the increasing need for cost-effective treatment options for chronic and complex diseases, enhancing patient access to vital therapies and reducing financial burdens on healthcare systems.

According to Roots Analysis' findings, these four companies are at the forefront of biosimilar development. Amgen, a US-based company established in 1980, has reported cumulative sales exceeding $10 billion from its biosimilars through Q3 2024. Pfizer, an American pharmaceutical giant founded in 1849, and Sandoz, established in Switzerland in 1886, are also prominent players.

Celltrion from South Korea, founded in 2002, has emerged as a global biosimilar developer. These companies leverage enhanced analytical tools and innovative manufacturing technologies to produce effective and high-quality biosimilars. The upcoming patent expirations of several blockbuster drugs are anticipated to create further opportunities within the biosimilar market.